Pediatric Cancer

This article aims to provide an EBP overview, empowering pediatric oncology nurses to deliver high-quality, evidence-based care, and ultimately improving outcomes for their patients during and after treatment. Read More ›

Cancer researchers continue to make progress in developing tests using liquid biopsies that could complement and even serve as an alternative to traditional tissue biopsies. Read More ›

On December 12, 2019, the FDA issued draft guidance to implement amendments to the Federal Food, Drug, and Cosmetic (FD&C) Act that will facilitate early assessment of studies of molecularly targeted oncology drugs that may be effective in the treatment of pediatric cancers. Read More ›

The past week in oncology-related news includes shortages of crucial pediatric cancer drug, results of a study of racial disparities in multiple myeloma, and new drug on the horizon for HER2 metastatic breast cancer. Read More ›

Chicago, IL—Approximately 25% of children, adolescents, and young adults with advanced cancer were eligible for a targeted therapy after genotyping of their tumors in the Pediatric Molecular Analysis for Therapy Choice (MATCH) clinical trial. That rate is more than double the 10% that researchers had projected. Read More ›

“Considering the frequency of both pediatric cancer survivorship and of late toxicities related to treatment, childhood cancer is often the cancer diagnosis that lasts a lifetime,” said Kerry Parsons, PharmD. Read More ›